Obesity is an exacerbated public health challenge, increasing the risk of several diseases and mortality while
deteriorating the quality of life. There is significant dedication to exploring obesity therapies using
glucagon-like peptide-1 (GLP-1) agonists, which have shown efficacy in reducing the number of deaths and
complications associated with type 2 diabetes. This research aimed to examine the recent search popularity
of GLP-1 agonists using Google Trends at both national (in Iraq) and global levels. To quantify relative
search volume (RSV), the total search query activity has been transformed to a percentage scale ranging
from 0% to 100%. The word "Ozempic" was chosen because of its extensive coverage in social media and
web/print publications pertaining to this subject matter. A comparative search was performed targeting the
phrases "Wegovy," "Saxenda," and "Mounjaro" to identify a novel combination GLP-1 agonist from August
2023 to August 2024. The present study demonstrated a statistically significant difference in the RSV among
the four drugs (P < 0.0001) nationally and globally. In Iraq, the highest RSV for Ozempic was documented in
Duhok, followed by Sulaymaniyah and Erbil. A comparable RSV profile has been noted for Saxenda, while
substantial interest in Wegovy is seen in Ninawa. Meanwhile, globally, the highest RSV for Ozempic was
recorded in Canada, the United States of America, and Australia. A distinct RSV profile has been observed
for Saxenda, with heightened search interest recorded in Latin America, Poland, Sweden, and Australia. By
contrast, Mounjaro received search interest primarily in Greenland and the United States, while Mounjaro
search interest was noted in Canada, the United States, and Australia. This study demonstrates a significant
and growing public interest in GLP-1 agonists, namely, Ozempic, Saxenda, Wegovy, and Mounjaro. As the
use of GLP-1 agonists for weight loss becomes more common, more knowledge, understanding, and
continuous scientific research will make it more convenient to obtain the best patient outcomes.